EQS-News: Marinomed Biotech AG announces results for the first half year of 2025
|
EQS-News: Marinomed Biotech AG
/ Key word(s): Half Year Results
Marinomed Biotech AG announces results for the first half year of 2025
Korneuburg, Österreich, September 17, 2025 - Marinomed Biotech AG (VSE:MARI) significantly increased both revenue and earnings in the first half of 2025. Revenue amounted to EUR 7.2 million (H1 2024: EUR 2.4 million). Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2 million), significantly influenced by other operating income of EUR 19.3 million, which includes a restructuring gain of EUR 18.9 million. Cash flow from operating activities was slightly negative at EUR –0.2 million. Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5 million, compared to EUR 0.9 million in the previous year. Balance sheet total decreased to EUR 7.6 million (December 31, 2024: EUR 8.2 million).
"The sale of the Carragelose business has significantly strengthened our financial base. We see this as an important intermediate step in advancing our pipeline of Marinosolv projects and building the foundation for sustainable growth. With the targeted approval of Budesolv, we have made significant operational progress in recent months. We are well on track. Our operational progress is also reflected in the development of our key figures—cash flow from operating activities has improved, however, still slightly negative. The recently announced capital measures have further strengthened our financial base," added Gabriele Ram, CFO of Marinomed.
"The planned convertible bond in the amount of EUR 2.5 million, as well as the capital increase of EUR 1.1 million announced yesterday not only strengthen our negotiating position with potential licensing partners for our development projects Budesolv and Tacrosolv, but also enable us to advance more rapidly on the operational side. Marinomed's current financial planning does not include any further capital measures,“ according to Andreas Grassauer, CEO of Marinomed.”
Selected financial figures for H1 2025
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forwardlooking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
17.09.2025 CET/CEST This Corporate News was distributed by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2199130 |
| End of News | EQS News Service |
|
|
2199130 17.09.2025 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Umsatzerlöse1 | 8,12 | 11,63 | 11,28 | 9,18 | 4,75 | 0,00 | 0,00 | |
| EBITDA1,2 | -5,39 | -3,54 | -4,24 | -4,45 | -6,54 | 0,00 | 0,00 | |
| EBITDA-Marge3 | -66,38 | -30,44 | -37,59 | -48,48 | -137,68 | 0,00 | 0,00 | |
| EBIT1,4 | -5,82 | -4,14 | -4,91 | -5,13 | -7,60 | 0,00 | 0,00 | |
| EBIT-Marge5 | -71,68 | -35,60 | -43,53 | -55,88 | -160,00 | 0,00 | 0,00 | |
| Jahresüberschuss1 | -6,01 | -5,89 | -6,40 | -6,80 | -15,42 | 0,00 | 0,00 | |
| Netto-Marge6 | -74,02 | -50,65 | -56,74 | -74,07 | -324,63 | 0,00 | 0,00 | |
| Cashflow1,7 | -6,89 | -4,87 | -5,20 | -4,53 | -2,40 | 0,00 | 0,00 | |
| Ergebnis je Aktie8 | -4,10 | -4,00 | -4,30 | -4,50 | -8,67 | -3,40 | -1,80 | |
| Dividende8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Marinomed Biotech | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| A2N9MM | ATMARINOMED6 | AG | 32,66 Mio € | 01.02.2019 | Halten | 8FWR88QM+8R |
| KGV 2027e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| -29,58 | 0,00 | 0,00 | -3,91 | -1,25 | -13,61 | 6,88 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 11.06.2026 | 08.05.2025 | 16.09.2026 | 11.03.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| -4,64% | +0,63% | -1,93% | +36,02% | -76,33% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
